<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642642</url>
  </required_header>
  <id_info>
    <org_study_id>IT-A-008</org_study_id>
    <nct_id>NCT00642642</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring</brief_title>
  <official_title>A Phase II/III Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Isolagen Therapy in the Treatment of Moderate to Sever Facial Acne Scarring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fibrocell Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fibrocell Technologies, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile and the treatment effect of
      Isolagen TherapyTM and placebo when administered to facial acne scars.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluator Live Acne Scarring Assessment Responders</measure>
    <time_frame>Baseline (prior to first treatment) and four months after last treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders.  On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject Live Acne Scarring Assessment Responders</measure>
    <time_frame>Baseline (prior to first treatment) and four months after last treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders.  On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluator Live Acne Scarring Assessment Responders</measure>
    <time_frame>Baseline (prior to first treatment) compared to one, two, and three months after last treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects who improved by 1 point or more on the Evaluator Live Acne Scarring Assessment (ELASA), as assessed by the evaluating Investigator, are counted as responders.  On the ELASA scale, a score of 0 (Clear) is best and a score of 4 (Severe) is worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Live Acne Scarring Assessment Responders</measure>
    <time_frame>Baseline (prior to first treatment) compared to one, two, and three months after last treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cheeks that improved by at least two points on the Subject Live Acne Scarring Assessment (SLASA) as scored by the subject were considered responders.  On the SLASA scale, a score of -2 (Very Dissatisfied) was worst and a score of 2 (Very Satisfied) was best.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Acne Scarring of the Face</condition>
  <arm_group>
    <arm_group_label>Double blinded active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive autologous fibroblast treatment on either their left or right side of their face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double blinded placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will receive placebo treatment on the opposite side of the face from active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Human Fibroblasts (azficel-T)</intervention_name>
    <description>Collection of 3 mm post auricular skin punch biopsies.
Administration of 3 study treatments administered 14 ± 7 days apart.</description>
    <arm_group_label>Double blinded active</arm_group_label>
    <other_name>LAVIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Collection of 3 mm post auricular skin punch biopsies.
Administration of 3 study treatments administered 14 ± 7 days apart.</description>
    <arm_group_label>Double blinded placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, between 18 years and 65 years of age.

          2. Investigator assessment of the acne scarring on each cheek of moderate to  severe.

          3. A history of acne scarring for more than 3 years.

          4. Subject assesses the appearance of both sides of their facial acne scars as
             dissatisfied or very dissatisfied with appearance.

        Exclusion Criteria:

          1. Significant active acne.

          2. Use of oral antibiotic or retinoid active acne therapy within one year of enrollment.

          3. Presence of hypertrophic scars on the cheeks.

          4. More than 20% of treatment area comprised of ice pick scars or sinus tracts

          5. Treatment area per cheek is less than 9 cm x cm

          6. Unilateral or unbalanced acne scar distribution.

          7. Physical attributes which prevent the assessment or treatment of the acne scars.

          8. Treatment with an investigational product or procedure within 30 days prior to study
             enrollment or plans to participate in another clinical trial during the course of
             this study.

          9. Previous treatment with Isolagen TherapyTM.

         10. Use of Isotretinoin within one year of enrollment into study.

         11. Use of permanent or semi-permanent dermal fillers in the treatment areas within
             defined time frames.

         12. Disorders or drugs that increase bleeding or clotting.

         13. Pregnant or lactating women or women trying to become pregnant during the study.

         14. Excessive exposure to sun.

         15. Smoking more than ½ pack of cigarettes per day.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brighton Medical Corporation</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Laser Institute for Dermatology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute, LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser, Skin and Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser and Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 19, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2008</firstreceived_date>
  <firstreceived_results_date>February 9, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
